ClinicalTrials.gg
Not yet recruitingNCT07679087PAIN-RLSUpdated Jul 1, 2026

Study of the Frequency and Characteristics of Pain Symptoms in Restless Legs Syndrome

An observational study in RLS, sponsored by University Hospital, Clermont-Ferrand. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Pain by University Hospital, Clermont-Ferrand — 8 open to participants now, 8 under way, 1 of them phase 3. Pain · University Hospital, Clermont-Ferrand.

Planned enrollment
3rd of 14
1,000 · median 230
Started
2026
with 4 others
Observational
14 of 45
2 open now
Registered
43rd of 45
by date

Among the 45 studies in Pain by University Hospital, Clermont-Ferrand, this one is the 3rd largest by planned enrollment of the 14 observational ones that give a count, is one of 5 that started in 2026, is one of 14 observational ones, and was the 43rd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

8 of the 45 studies in Pain by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Pain by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

Restless Legs Syndrome (RLS) is a neurological disorder affecting between 4% and 29% of adults. It is characterized by an urge to move the legs or other parts of the body, often accompanied by unpleasant and sometimes painful sensations. The pathophysiology of RLS, whether associated with pain or not, remains poorly understood, and only a limited number of studies have specifically investigated this aspect.

The aim of this study is to determine the prevalence of the painful component of symptoms in a large cohort of patients with RLS, to further characterize its clinical features, and to assess its impact on patients' quality of life. This work could improve the identification of patients experiencing pain, enhance our understanding of pain characteristics in RLS, and help optimize patient management. Furthermore, in the context of emerging therapeutic approaches such as neuromodulation, a better characterization of pain in RLS may contribute to the development and evaluation of new treatment strategies. This is particularly relevant given the high prevalence of RLS and its substantial impact on patients' quality of life.

Participants will be recruited either through their neurologist during routine follow-up visits at the Neurology Department of Clermont-Ferrand University Hospital or through the France Ekbom Association. Individuals interested in participating will be provided with access to the online questionnaire via a QR code or a dedicated web link. One thousand patients will be include in this study (RIPH type 3). The online questionnaire is expected to take approximately 30 minutes to complete. It includes the collection of demographic data (age, sex, lifestyle factors, weight, height, employment status, comorbidities, and dietary habits), as well as questions regarding the patient's medical history and sleep habits.

The questionnaire also includes validated instruments assessing sleep, pain, RLS severity, anxiety and depression, and quality of life.

At the end of the questionnaire, participants will be invited to take part in an optional ancillary study aimed at validating the French translation of the Restless Legs Syndrome Quality of Life questionnaire (RLS-QOL). Participants who agree to participate will complete the questionnaire once at baseline and will subsequently receive an email reminder to complete it a second time two weeks later. This test-retest procedure will be used to assess the reproducibility of the French-adapted version of the questionnaire.

03

Conditions studied

  • RLS

Browse trials for

Keywords

  • RLS
  • Pain
  • Sleep
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be contacted through the France Ekbom Association or identified during routine consultations. Those who are interested in participating in the study will be able to access the online questionnaire via a QR code or a web link.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 years or older.
  • Diagnosis of Restless Legs Syndrome (RLS) according to the criteria of the International Classification of Sleep Disorders, Third Edition (ICSD-3).
  • French-speaking.

Exclusion criteria

Exclusion Criteria:

  • Patient under guardianship, curatorship, or legal protection measures.
  • Patient who has never had an appointment with a neurologist as part of their SJSR care pathway.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • RLS patient

    Patients with a diagnosis of Restless Legs Syndrome (RLS) confirmed by a sleep specialist

    Other: Patients with RLS

Interventions

  • OtherPatients with RLS

    The online questionnaire is expected to take approximately 30 minutes to complete. It includes the collection of demographic data (age, sex, lifestyle factors, weight, height, employment status, comorbidities, and dietary habits), as well as questions regarding the patient's medical history and sleep habits. The questionnaire also includes validated instruments assessing sleep, pain, RLS severity, anxiety and depression, and quality of life. At the end of the questionnaire, participants will be invited to take part in an optional ancillary study aimed at validating the French translation of the Restless Legs Syndrome Quality of Life questionnaire (RLS-QOL). Participants who agree to participate will complete the questionnaire once at baseline and will subsequently receive an email reminder to complete it a second time two weeks later.

06

What researchers measure

Primary outcomes

  1. Pain evaluation according to the Brief Pain Inventory (PBI)

    Time frame: at day 0

Secondary outcomes

  1. Pain characteristics using the DN4 questionnaire

    Time frame: at day 0

  2. RLS severity using the International Restless Legs Syndrome Rating Scale (IRLS)

    Time frame: at day 0

  3. Fibromyalgia using the FIRST (Fibromyalgia Rapid Screening Tool)

    Time frame: at day 0

  4. Biopsychosocial dimensions of pain according to the Pain Catastrophizing Scale (PCS).

    Time frame: at day 0

  5. Anxiety and depression using the Hospital Anxiety and Depression Scale (HADS)

    Time frame: at day 0

  6. Quality of life using the EQ-5D-5L

    Time frame: at day 0

  7. Daytime sleepiness using Epworth Sleepiness Scale (ESS).

    Time frame: at day 0

  8. RLS-specific quality of life using the Restless Legs Syndrome Quality of Life questionnaire (RLS-QOL).

    Time frame: at day 0

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Aug 2027, 13 months later.

Of 505 non-industry observational studies under Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 13 months is below that.

Counting every sponsor, half of 520 studies reached it within 18 months; a quarter within 8 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 1, 2026
StartEst.
Jul 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07679087
Responsible party
Sponsor
First posted
Jul 1, 2026
Start date
Jul 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
+33473754963
Livia FANTINI
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion